Skip to main content

Table 1 Breast cancer risk associated with estrogen-alone therapy (ET) in women with hysterectomy and estrogen plus progestin therapy (EPT) in women with intact uteri; restricted to postmenopausal women with follow-up MHT information in 2004 the National Institutes of Health-AARP Diet and Health Study cohort

From: Use of postmenopausal hormone therapies and risk of histology- and hormone receptor-defined breast cancer: results from a 15-year prospective analysis of NIH-AARP cohort

  Women with hysterectomy (n = 28,614) Women with intact uteri (n = 39,996)
  N cases HR (95%CIs) N cases HR (95%CIs)
Total 940   1539  
MHT use ET EPT
 Never 232 1.00 (referent) 436 1.00 (referent)
 Ever 708 0.90 (0.74–1.11) 1103 1.20 (1.06–1.37)
Ever MHT use
 BMI < 25 420 0.88 (0.62–1.24) 695 1.32 (1.09–1.61)
 BMI 25 < 30 284 1.10 (0.75–1.62) 479 1.10 (0.87–1.39)
 BMI ≥ 30.0 214 0.74 (0.51–1.07) 338 1.21 (0.91–1.62)
   ptrend = 0.87   ptrend < 0.0001
Recency
 Former 596 0.77 (0.62–0.96) 1023 1.14 (0.99–1.30)
 Current 112 1.35 (1.04–1.75) 80 1.80 (1.39–2.32)
Duration, years
 < 5 20 0.77 (0.39–1.50) 164 0.83 (0.64–1.08)
 5–9 35 0.90 (0.55–1.48) 184 1.04 (0.81–1.32)
 10–14 85 1.05 (0.73–1.51) 296 1.37 (1.12–1.68)
 15–19 106 1.12 (0.80–1.56) 227 1.39 (1.11–1.75)
 ≥ 20 254 0.93 (0.72–1.21) 113 1.21 (0.86–1.72)
   ptrend = 0.57   ptrend = 0.002
Time since last use, former users, years
 < 5 193 0.69 (0.47–1.02) 358 1.23 (0.96–1.58)
 5–9 80 0.82 (0.60–1.12) 189 1.18 (0.98–1.42)
 ≥ 10 78 0.80 (0.57–1.13) 92 1.18 (0.93–1.49)
   ptrend < 0.0001   ptrend < 0.0001
  1. ET-alone analysis is restricted to women with hysterectomy. EPT analysis includes women with intact uterus
  2. MHT hormone therapy; p values bold < 0.05